Trials (Centre François Baclesse): Revision history

14 December 2025

• curprev 18:4418:44, 14 December 2025‎ Francine talk contribs‎ 131,165 bytes +213‎ No edit summary undo

6 December 2025

• curprev 12:4012:40, 6 December 2025‎ Lucas talk contribs‎ m 130,952 bytes +1,701‎ Update categories. undo

2 December 2025

• curprev 20:5320:53, 2 December 2025‎ Francine talk contribs‎ 129,251 bytes +48‎ No edit summary undo
• curprev 13:5813:58, 2 December 2025‎ Lucas talk contribs‎ m 129,203 bytes +16,301‎ Update categories. undo

4 January 2024

• curprev 18:3918:39, 4 January 2024‎ Francine talk contribs‎ 112,902 bytes +19‎ No edit summary undo
• curprev 18:3818:38, 4 January 2024‎ Francine talk contribs‎ 112,883 bytes +1,817‎ No edit summary undo

1 December 2023

• curprev 22:1722:17, 1 December 2023‎ Francine talk contribs‎ 111,066 bytes +99‎ No edit summary undo
• curprev 22:1622:16, 1 December 2023‎ Francine talk contribs‎ 110,967 bytes +110,967‎ Created page with "'''NCTID''': NCT01827943 '''Title''': Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer '''Study Summary''': In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival. '''Sponsor''': Institut Bergonié '''Intervention''': Temsirolimus '''Start Date''': 2009-06 '''Last Updated''..."